Approximately 25–35% of patients with AT/RT carry a germline SMARCB1 alteration that defines the Rhabdoid Tumour Predisposition Syndrome type 1 (RTPS1; MIM #609322) [12, 13, reviewed by 14]. Here, SMARCB1 is linked to rhabdoid tumor predisposition syndrome 1.